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Abstract Background. Epstein-Barr virus (EBV)-
associated post-transplantation Iymphoproliferative dis-
ease (PTLD) develops in 1 to 10 percent of transplant 
recipients, in whom it can be treated by a reduction in the 
level of immunosuppression. We postulated that the tissue 
expression of the small RNA transcribed by the EBER-1 
gene during latent EBV infection would identify patients at 
risk for PTLD. 
Methods. We studied EBER-1 gene expression in liver 
specimens obtained from 24 patients 2 days to 22 months 
before the development of PTLD, using in situ hybridiza-
tion with an oligonucleotide probe. Control specimens 
were obtained from 20 recipients of allografts with signs of 
injury due to organ retrieval, acute graft rejection, or viral 
hepatitis in whom PTLD had not developed 9 to 71 months 
after the biopsy. 
POST-TRANSPLANTATION Iymphoproliferative disease (PTLD), either polyclonal or monoclonal, 
complicates the clinical course of I to 10 percent of 
organ-transplant recipients. I •3 Immunohistochemical 
studies have demonstrated that the lymphoid cells 
within the lesions of PTLD almost invariably contain 
Epstein-Barr virus (EBV), primarily in a state of la-
ten t infection.4 ,5 
The EBER-I gene is expressed early during latent 
EBV infection and codes for a small messenger RNA 
(mRNA) expressed at up to 107 copies per eel\.6 We 
and others have previously demonstrated the value of 
the detection of EBER-I RNA for identifying EBV-
infected cells in formalin-fixed paraffin-embedded tis-
sues. 7,8 
In the current investigation, we used in situ hybridi-
zation to examine a series of liver-biopsy specimens 
from pediatric liver recipients in whom PTLD devel-
oped, as well as a control group of patients in whom 
this disorder did not develop, for evidence of cells ex-
pressing the EBER-I gene. We found that such ex-
pression may permit early identification of patients at 
risk for PTLD. 
METHODS 
By reviewing the autopsy and surgical pathology files at the Chil· 
dren's Hospital of Pittsburgh for the years 1982 through 1989, we 
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Results. Of the 24 patients with PTLD, 17 (71 percent) 
had specimens in which 1 to 40 percent of mononuclear 
cells were positive for the EBER-1 gene. In addition, 10 of 
these 17 patients (59 percent) had specimens with histo-
pathological changes suggestive of EBV hepatitis. In ev-
ery case, EBER-1-positive cells were found within the 
Iymphoproliferative lesions identified at autopsy, Only 2 of 
the 20 controls (10 percent) had specimens with EBER-
1-positive cells (P< 0.001), and such cells were rare. 
Conclusions. EBER-1 gene expression in liver tissue 
precedes the occurrence of clinical and histologic PTLD. 
The possibility of identifying patients at risk by the method 
we describe here and preventing the occurrence of PTLD 
by a timely reduction of immunosuppression needs to be 
addressed by future prospective studies. (N Engl J Med 
1992;327:1710-4.) 
identified 24 liver recipients who met the two criteria for entry to our 
study: PTLD had been diagnosed histopathologically,3 and at least 
one liver-biopsy specimen obtained before the diagnosis of PTLD 
was available for evaluation, 
Control patients were drawn from the same files as the patients 
with PTLD. The controls had had no documented PTLD during a 
follow-up period of at least nine months after the performance of the 
liver biopsy yielding a specimen selected to serve as a control. Perti-
nent clinical information about the group with PTLD and the con-
trol group was obtained from medical records. Histopathological 
evaluation of the liver specimens selected for study was performed 
on 4-p,m sections of tissue routinely embedded in paraffin and 
stained with hematoxylin and eosin. 
The in situ hybridization studies of EBV RNA were performed 
with a 30-base digoxigenin-Iabeled oligonucleotide complementary 
to a portion of the EBER-I gene. The details of the technique have 
been published elsewhere.s The appearance of a brown or blue-
brown color in the nucleus was considered a positive reaction. This 
method has previously detected EBV RNA from an EBV-infected 
Raji-celiline, but does not detect EBV in the T-cell line Molt, which 
does not contain EBV. Lymphoid tissue from an EBV-seronegative 
patient and tissues infected with herpes simplex virus type I , papil-
lomavirus type 16, and adenovirus showed no cross-reactivity. Tis · 
sue from a patient with PTLD who was known to be positive for 
EBV served as a positive control in each run. Any slide negative for 
EBV RNA was tested for preservation of RNA with the use of a 
polydeoxythymidine probe 9 ,tO 
The frequency of EBV -infected cells was determined in a semi-
quantitative fashion by counting the total number of EBER-l cells 
in relation to the total number of lymphocytes seen in parallel sec-
tions prepared from the same biopsy specimen and stained with 
hematoxylin and eosin. The cells in the hepatic sinusoids and portal 
tracts were counted. In small specimens, all available cells were 
counted; in larger specimens, every second o( third portal tract was 
examined . 
Immunohistochemical in situ hybridization studies with double 
labeling were performed on liver blocks obtained at autopsy f(Om 
four patients with fatal PTLD. Initially, the immunohistochemical 
reaction was performed according to a previously published meth-
od." The antibodies used were directed against LCA (Dako, Car-
pinteria , Calif.), CD20 (L26, D ako), CD43 (Leu 22, Becton Dickin-
son, Mountain View, Calif.), Cam 5.2 (Becton Dickinson ), and a 
mixture of anti-keratin antibodies composed of AE, (Hybritech , 
San Diego, Calif. ), Cam 5.2 , VCD3 (Triton Biosc iences , Alamed a, 
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Table 1. Clinicopatholc;>gical Features and EBER-1 
Gene Expression in Liver Recipients. 
CONTROL GROUP GROUP WITH PTLD 
FEATURE (N ~ 20) (N ~ 24) 
Age range (median) - yr 0.8-16 (7.0) 0.5-25.0 (3.7) 
Sex - M!F 1218 10114 
no. wilhjeatuTelno. Studied (%) 
EBER-I positivity 2120 (10) p/24 (71)" 
EBV seropositivityt 7115 (47) 10/16 (62) 
Liver histopathology 
CeUular rejection or 15/20 (75) 5/24 (21) 
ischemic injury:!: 
Hepatitis§ 5/20 (25) 17/24 (71) 
"'P<O.OOI for comparison of the control group with the group with 
PTLD, by Fisher's exact test. 
tFor details of serologic testing for EBV, see the tUl. 
tChanges reflecting graft rejection and ischemic injury were frequently 
concurrent. 
§Hepalitis was albibuted to cytomegalovirus or non-A, non-8 hepatitis 
virus in Ihe control group. and generally 10 EBY in !he group wilh PTLD. 
The latter group included five patients with COllCWTeot hepatitis and rejec-
tion (see !he leX! [01' detailed histopathological findings). 
Calif.), and GN-2 (Enzo Biochemicals, New York). Thereafter, in 
situ hybridization studies were performed as outlined above. 
REsULTS 
The group with PTLD comprised 10 male and 14 
female patients. Their ages at the time of transplanta-
tion ranged from 6 months to 25 years (median, 3.7 
years). Their diagnoses included a variety of liver dis-
orders, such as biliary atresia, cryptogenic cirrhosis, 
alphal-antitrypsin deficiency, hereditary cholestasis, 
and hyperalimentation injury. One patient had re-
ceived a heart transplant for idiopathic cardiomyopa-
thy. The onset of PTLD occurred a median of 12.5 
weeks after transplantation (range, 5 to 640). The ana-
romical sites involved by PTLD when it was first diag-
nosed were the liver (seven patients), the tonsils or 
adenoids (five patients), the gastrointestinal tract (five 
patients) , the trachea (one patient), the bile duct (one 
patient), the meninges (one patient), and the lymph 
nodes (one patient); in three patients the disease was 
d isseminated. 
T he control group consisted of 12 male and 8 female 
pa tients 10 months to 16 years old (median, 7 years). 
T he spe trum of primary diseases requiring trans-
plantation in this group was similar to that in the 
group with PTLD. The biopsy specimens selected as 
controls were obtained 5 to 1790 days after transplan-
ta tion (median, 27.5). Histopathological examination 
generally showed varying degrees of cellular rejection 
with or without injury due to organ retrieval, as as-
sessed by standard criteria. 12 Two controls had non-A, 
non-B hepatitis, and three had cytomegalovirus hepa-
titis (Table I). These controls had no evidence of 
PTLD during clinical follow-up lasting 9 to 71 months 
after liver biopsy (median, 30). 
In si tu hybrid ization studies for EBER-I expression 
revealed that in 17 of the 24 patients with PTLD 
(7 1 percent), one or more Hver specimens obtained 
before the development of PTLD contained from 
1 percent to 40 percent EBER-I mRNA-positive 
mononuclear cells in the portal tracts and sinusoids 
(Fig. I and 2). In contrast, only 2 of 20 controls (10 
percent) had mononuclear cells containing EBER-I 
mRNA (P<O.OOI by Fisher's exact test); in both these 
controls, less than 1 percent of the cells were positive. 
A 
B 
Figure 1. Lymphocytic Infiltration of the Hepatic Portal Tracts by 
Mononuclear CeWs Positive for EBER-1 mRNA in a Patient with 
EBV-Associated Hepatitis. 
Panel A (x210) shows scattered EBER-1-positive nuclei in ap-
proximately 20 percent of the lymphocytes infiltrating the portal 
tract. Panel B (hematoxylin and eosin, x210) shows an infiltrate 
of activated lymphocytes involving the portal vein and simulating 
graft rejection. 
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Generally, the positive cells were small lymphocytes, 
although some were as large as 20 IJ-m . Hepatocytes, 
bile-duct epithelial cells, and endothelial cells did not 
hybridize with the EBER-I probe. In the group with 
PTLD, the interval between the detection of EBER-I 
mo:D~A in mononuclear cells and the development of 
PTLD ranged from 0 to 50 days in 10 patients and 
from 51 to 100 days in 3 patients; it was more than 100 
A 
• 
• 
B 
Figure 2. Lymphocytic Infiltration of the· Hepatic Sinusoids by 
EBER-1-Positive Cells in a Patient with EBV-Associated 
Hepatitis. 
In Panel A (X210), the sinusoids contain aggregates oflympho-
cytes, and the hepatocytes show focal hydropic swelling, steato-
sis, and nuclear pyknosis. In Panel B (x210), the sinusoids also 
contain EBER-1-positive lymphocytes. 
Figure 3. PTLD Involving a Portal Tract (x 420). 
Approximately 70 percent of the cells are EBER-1-positive, with 
both the small round lymphocytes and the large immature lym-
phocytes affected. The bile-duct epithelium in the center of the 
field is stained with anti-Cam 5.2 antibody and does not show 
evidence of EBV infection. 
days in 4 patients. In I of these 17 patients, rare 
EBER-I mRNA-positive cells were detected 660 days 
before the onset of PTLD. In 10 of the 17 patients in 
whom EBV-positive cells were identified, the subse-
quent PTLD involved the liver, whereas in the other 
7 patients it involved other organs. Expression of the 
EBER-I gene could be demonstrated in each of II 
specimens of tissue involved by PTLD that were stud-
ied by in situ hybridization (Fig. 3). These tissues 
contained abundant EBER-I-positive mononuclear 
cells, which accounted for more than 80 percent of 
the total lymphoid-cell population in some patients. 
Small round lymphocytes as well as cells with blastic 
transformation contained EBV mRNA. As in three 
previously reported cases of PTLD,13 rare hepato-
cytes also showed staining for EBER-I mRNA (Fig. 
4). Bile-duct epithelial cells and endothelial cells 
were negative in all patients . Double-labeling studies 
showed that the majority of the lymphoid cells pos-
itive for EBER-I mRNA had membranes positive 
for CD20, .a finding consistent with B-celilineage (Fig. 
5). However, cells coexpressing CD43 and EBER-I 
mRNA, presumably representing T cells, were also 
present in small numbers. 
Serologic data temporally related to the biopsy were 
obtained for 16 of the 24 patients with PTLD (through 
the courtesy of Dr. M .C. Breinig, University of Pitts-
burgh). Six patients were judged either to be seronega-
tive for EBV or to have titers transiently positive for 
EBV because of multiple perioperative blood transfu-
sions; all were negative for EBER-I mRNA. The other 
10 patients were seropositive and found to be positive 
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Figure 4. Fatal PTLD Involving Hepatocytes (x630) . 
Rare EBER-1 - positive nuclei were found In cells conclusively 
identified as hepatocytes, by simultaneous immunohistochemical 
evaluation with the anti-keratin antibody Cam 5. 2. 
for EBER- I mRNA as well. Serologic data were avail-
able for 15 of the 20 controls_ Both EBER- I- positi e 
controls were seropositive for EB ; one was undergo-
ing primary seroconversion a t the time of biopsy. Five 
controls were seropositive for EBV but EBER-I - neg-
ative. The eigh t other controls were seronegative as 
well as EBER- I- negative. 
Histopathological examination. of liver specimens 
from the 17 patients wi th PT LD whos mononuclear 
cells were positi e for EBER-I mRNA showed that 15 
patien ts had changes ind icating EBV hepati tis, con-
sis ting of activa ted mononuclear infiltrates in the por-
tal tracts associa ted with lobular d isarray and sinusoi-
dal lymphocytes arranged in linear beads and small 
aggregates. One patient had mononuclear inflamma-
tory infiltrates that spared the porta l tracts a nd resem-
bled lobular hepatitis. Five patients, in add ition to the 
changes of EBV hepatitis , had a mixed lymphocytic, 
polymorphonuclear, and eosinophilic portal-tract in-
filtrate associa ted with bile-duct injury, indicating a 
mild acute cellular rejection. One patient had a necro-
tizing granulomatous hepatitis with adenovirus inclu-
sions. When PTLD supervened in the patients with 
EBV hepatitis, the mononuclear-cell infiltrates ex-
panded and acquired atypical nuclear characteristics. 
Liver specimens obtained from 7 of the 24 patients 
before PTLD developed were negative for EBER-I 
mRNA. The histologic correlates of these tissues were 
mild acute cellular rejection with or without coexist-
ing injury due to organ retrieval (five patients) or 
injury due to hyperalimentation (one patient); non-
specific changes consisting of mild hepatocellular 
swelling with scattered polymorphonuclear leukocytes 
and lymphocytes in the sinusoids were observed in one 
patient (Table I ). 
DISCUSSION 
The oropharyngeal mucosa, parotid and lacrimal 
glands, lymph nodes , and circulating lymphocytes are 
known to be anatomical sites where latent EBV may 
persist after acute infectious mononucleosis 8 , 14-17 The 
present study indicates that lymphocytes of the hepa t-
ic portal tract and sinusoids can also harbor EBV, and 
that an increase in the number of EBER-l-positive 
cells precedes clinically and histologically evident 
PTLD. The detection of such EBV-positive cells in 
the absence of evidence of graft rejection should 
prompt the physician to consider decreasing the level 
of immunosuppression, since EBV infections , even 
when PTLD is advanced, are responsive to immuno-
modulation.2 Prospective studies will be necessary to 
assess the positive predictive value of EBER-I-posi-
tive cells in regard to the possible development of 
PTLD in a particular patient. 
The presence of EBV-positive lymphoid cells before 
the occurrence of lymphoproliferative dis ase has also 
been observed in lymph nodes from pa tients with the 
acquired immunodeficiency syndrome; this finding is 
consistent with current notions of a multistep process 
of carcinogenesis induced by EBV. 18-21 The possible 
role of EBER- I mRNA in the evolution of PTLD is 
unknown, bu t it has been suggested that EBER- I 
genes direct the synthesis of critical viral proteins in 
vivoY . 
The fact that EBV-positive cells in PTLD lesions 
Figure 5. EBV-Infected Lymphocytes in the Lesions of PTLD 
(X420) . 
Immunohistochemical evaluation with anti-CD20 antibody, com-
bined with in situ hybridization, showed that in PTLD the majority 
of EBV-infected lymphocytes are B cells. Cells positive for CD20 
are stained brown, and those positive for EBER-1 mRNA are 
stained blue-black. 
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were generally positive for CD20 is consistent with the 
notion that the EBV receptors required for the virus to 
enter the cells are normally found on B cells. 23 The less 
frequent occurrence of EBER-l mRNA in CD43-posi-
tive cells adds to growing evidence that benign as well 
as neoplastic T ells can occasionally be infected with 
EBV .8,24,25 
Several authors have described the histopathologi-
cal features of clinically presumed EBV hepatitis in 
patients who were not graft recipients26.28 and in recip-
ients of liver allografts .29 O ur study documents the 
presence of EBV -infected cells in the liver tissue of 
transplant recipients . EBV hepatitis in liver allografts 
may be overlooked if the pathologist does not pay 
close attention to lobular disarray and sin usoidallym-
phocytosis. The demonstration of the presence of a 
virus by in situ hybridizat ion is very helpful in reach-
ing a diagnosis when mononuclear infiltrates are sub-
tle, but it is unnecessary when numerous transformed 
lymphocytes can be clearly seen within the sinusoids, 
arranged in d iscrete aggregates and linear chains. 
Howev r, serologic data should be obtained in the 
latter case, sin e non-A, non-B hepatitis can cause 
similar changes 3 0 
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